Study population: clinical features and macrovascular involvement. Data are n (%) unless otherwise indicated.
| Age, yrs, mean ± SD | 65.5 ± 14 |
| Sex | |
| Female | 53 (88.3) |
| Male | 7 (11.7) |
| Subset | |
| Limited | 40 (66.7) |
| Diffuse | 20 (33.3) |
| RP duration, yrs, mean ± SD | 22.6 ± 13.4 |
| Disease duration, yrs, mean ± SD | 15.3 ± 8.7 |
| Autoantibodies | |
| ACA | 24 (40) |
| Scl70 | 23 (38.3) |
| ACA + Scl70 | 2 (3.3) |
| Other | 11 (18.4) |
| Videocapillaroscopy | |
| Early | 9 (15) |
| Active | 18 (30) |
| Late | 33 (55) |
| mRSS | 9.8 ± 10.2 |
| Smokers | |
| Yes | 7 (11.7) |
| No | 48 (80) |
| Ex-smoker | 5 (8.3) |
| Arterial hypertension | 31 (51.7) |
| Hypercholesterolemia | |
| Increased total cholesterol | 10 (16.7) |
| Increased LDL cholesterol | 20 (33.3) |
| Low HDL cholesterol | 9 (15) |
| Hypertriglyceridemia | 10 (16.7) |
| Diabetes mellitus | 2 (3.3) |
| Intermittent claudication | 10 (16.8) |
| Upper limb ulcers | 48 (80) |
| Ulcers in the other sites | 14 (23.3) |
| Calcinosis | 22 (36.7) |
| Gastrointestinal involvement | 60 (100) |
| GERD | 60 (100) |
| Other | 9 (15) |
| Interstitial lung disease | 32 (53.3) |
| Pulmonary arterial hypertension | 9 (15) |
| Peripheral arterial disease | 17 (18.3) |
| Not hemodynamically significant | 7 (41.2) |
| Hemodynamically significant | 10 (58.8) |
| Venous insufficiency | 18 (30) |
ACA: anticentromere autoantibodies; mRSS: modified Rodnan skin score; LDL: low-density lipoprotein; HDL: high-density lipoprotein; GERD: gastroesophageal reflux disease; RP: Raynaud phenomenon.